CB03-154

CB03-154
Clinical data
Other namesCB-03; CB03; CB-003; CB003
Routes of
administration		Oral
Drug classKv7.2 and Kv7.3 potassium channel opener
Identifiers
  • N-[2-(4-fluorophenyl)-5,7-dimethyl-3,4-dihydro-1H-isoquinolin-6-yl]-2-(1-methylcyclopropyl)acetamide
PubChem CID
Chemical and physical data
FormulaC23H27FN2O
Molar mass366.480 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(CCN(C2)C3=CC=C(C=C3)F)C(=C1NC(=O)CC4(CC4)C)C
  • InChI=1S/C23H27FN2O/c1-15-12-17-14-26(19-6-4-18(24)5-7-19)11-8-20(17)16(2)22(15)25-21(27)13-23(3)9-10-23/h4-7,12H,8-11,13-14H2,1-3H3,(H,25,27)
  • Key:GQOKKEDNOCHTOP-UHFFFAOYSA-N

CB03-154 is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of amyotrophic lateral sclerosis (ALS), epilepsy, major depressive disorder, bipolar disorders, stroke, and pain in China. It is taken orally. The drug is said to have higher selectivity and stability compared to retigabine. CB03-154 is under development by Shanghai Zhimeng Biopharma. As of November 2025, it is in 2/3 clinical trials for ALS, phase 2 trials for epilepsy and major depressive disorder, phase 1 trials for bipolar disorders, and the preclinical research stage of development for stroke, whereas no recent development has been reported for pain.

See also